← Back to patent-cliff list
CAS 107-21-1
1,2-Dihydroxyethaneethane-1,2-diol
Codes: 101438-16-a, (IV)409139-6-a, CRISA-006, Tamsulosin Hydrochloride-108, MACI-010, BOSE-009
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateTransthyretin amyloidosisTafamidisHeart diseaseTafamidisAtopic dermatitisCrisaboroleDermatitisCrisaboroleEczemaCrisaboroleAlopecia areataCrisaboroleLocalised sclerodermaCrisaborolePlaque psoriasisCrisaboroleErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinPulmonary arterial hypertensionMacitentanPulmonary hypertensionMacitentanChronic diseaseMacitentanChronic thromboembolic pulmonary hypertensionMacitentanThromboembolismMacitentanAngina pectorisMacitentanLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochloridePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel溃疡Bosentan HydratePulmonary arterial hypertensionBosentan HydratePulmonary hypertensionBosentan HydrateSystemic sclerosisBosentan Hydrate冠状血管痉挛Bosentan Hydrate大动脉炎Bosentan Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Tafamidis | Tier C — Watch / trade | - |
| Crisaborole | Tier C — Watch / trade | - |
| Tadalafil/Tamsulosin | Tier C — Watch / trade | - |
| Macitentan | Tier B — Position early | - |
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Bosentan Hydrate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-ol→[(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-yloxy](tert-butyl)dimethylsilane→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-one→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-yl trifluoromethanesulfonate→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodecan-11-one→methyl (4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-carboxylate→(4'aS,5'S,8'aR)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-ylmethanol→(4'aS,5'S,7'R,8'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-8'-(hydroxymethyl)-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-7',8'-diol→(1'S,2'S,5'R,7'S,8'S)-7'-[(tert-butyldimethylsilyl)oxy]-8'-methyl-4'-oxaspiro[1,3-dioxolane-2,11'-tricyclo[6.4.0.0(2,5)]dodecane]-2'-ol→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,5R,7S,8S)-2,7-bis[(tert-butyldimethylsilyl)oxy]-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-methyl-7-oxabicyclo[4.2.0]octane-2,3-dicarbaldehyde→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octane-3-carbaldehyde→[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]lithium→(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione→tert-butyl({[(1S,2S,3S,4S,6R)-4-[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octan-1-yl]oxy})dimethylsilane→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octane-2-carbaldehyde→1-lithio-1-(methoxymethoxy)ethene→1-[(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octan-2-yl]-2-(methoxymethoxy)prop-2-en-1-one→1,2-Dihydroxyethane
1,3-Dichloro-5-(trimethoxymethyl)benzene→(±)-1,2,4-Butanetriol→1-(3,5-Dichlorophenyl)-2,7,8-trioxabicyclo[3.2.1]octane→1,2-Dihydroxyethane→2-(3,5-Dichlorophenyl)-2-methoxy-1,3-dioxolane→cis-Cyclohexane-1,3,5-triol→3-(3,5-Dichlorophenyl)-2,4,10-trioxaadamantane→(4-Carboxy-2-hydroxyphenyl)amine→2-(3,5-Dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
1,3-Dioxolan-2-one→1-Hydroxy-2-ethoxybenzene→2-(2-Ethoxyphenoxy)ethanol→2-(2-Ethoxyphenoxy)ethyl mesylate→1,2-Dihydroxyethane→1,2-Dimethylsulfonyloxyethane→5-(2-Aminopropyl)-N-tert-butyl-2-methoxybenzene-1-sulfonamide→N-tert-Butyl-2-methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(±)-N-tert-Butyl-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide→(±)-5-(2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide
2-(4-bromophenyl)acetic acid→methyl 2-(4-bromophenyl)acetate→dimethyl carbonate→dimethyl 2-(4-bromophenyl)malonate→formimidamide hydrochloride→5-(4-bromophenyl)pyrimidine-4,6-diol→5-(4-bromophenyl)-4,6-dichloropyrimidine→potassium (N-propylsulfamoyl)amide→MACI-009→ethane-1,2-diol→MACI-011→5-bromo-2-chloropyrimidine→sulfurisocyanatidic chloride→2-methylpropan-2-ol→tert-butyl chlorosulfonylcarbamate→propan-1-amine→tert-butyl N-propylsulfamoylcarbamate→MACI-018
Solifenacin Succinate/Tamsulosin HydrochlorideOptimised routesteps: 7total yield: 165g(Racemic Tamsulosinc (Free))
1,3-Dioxolan-2-one→1-Hydroxy-2-ethoxybenzene→2-(2-Ethoxyphenoxy)ethanol→2-(2-Ethoxyphenoxy)ethyl mesylate→1,2-Dihydroxyethane→1,2-Dimethylsulfonyloxyethane→5-(2-Aminopropyl)-N-tert-butyl-2-methoxybenzene-1-sulfonamide→N-tert-Butyl-2-methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(±)-N-tert-Butyl-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide→(±)-5-(2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide
Dutasteride/Tamsulosin HydrochlorideOptimised routesteps: 7total yield: 165g(Racemic Tamsulosinc (Free))
1,3-Dioxolan-2-one→1-Hydroxy-2-ethoxybenzene→2-(2-Ethoxyphenoxy)ethanol→2-(2-Ethoxyphenoxy)ethyl mesylate→1,2-Dihydroxyethane→1,2-Dimethylsulfonyloxyethane→5-(2-Aminopropyl)-N-tert-butyl-2-methoxybenzene-1-sulfonamide→N-tert-Butyl-2-methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(±)-N-tert-Butyl-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide→(±)-5-(2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide
1,3-Dioxolan-2-one→1-Hydroxy-2-ethoxybenzene→2-(2-Ethoxyphenoxy)ethanol→2-(2-Ethoxyphenoxy)ethyl mesylate→1,2-Dihydroxyethane→1,2-Dimethylsulfonyloxyethane→5-(2-Aminopropyl)-N-tert-butyl-2-methoxybenzene-1-sulfonamide→N-tert-Butyl-2-methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(±)-N-tert-Butyl-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide→(±)-5-(2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide
(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-ol→[(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-yloxy](tert-butyl)dimethylsilane→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-one→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-yl trifluoromethanesulfonate→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodecan-11-one→methyl (4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-carboxylate→(4'aS,5'S,8'aR)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-ylmethanol→(4'aS,5'S,7'R,8'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-8'-(hydroxymethyl)-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-7',8'-diol→(1'S,2'S,5'R,7'S,8'S)-7'-[(tert-butyldimethylsilyl)oxy]-8'-methyl-4'-oxaspiro[1,3-dioxolane-2,11'-tricyclo[6.4.0.0(2,5)]dodecane]-2'-ol→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,5R,7S,8S)-2,7-bis[(tert-butyldimethylsilyl)oxy]-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-methyl-7-oxabicyclo[4.2.0]octane-2,3-dicarbaldehyde→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octane-3-carbaldehyde→[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]lithium→(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione→tert-butyl({[(1S,2S,3S,4S,6R)-4-[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octan-1-yl]oxy})dimethylsilane→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octane-2-carbaldehyde→1-lithio-1-(methoxymethoxy)ethene→1-[(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octan-2-yl]-2-(methoxymethoxy)prop-2-en-1-one→1,2-Dihydroxyethane
2-methoxyphenol→diethyl 2-bromomalonate→diethyl 2-(2-methoxyphenoxy)malonate→pyrimidine-2-carboximidamide hydrochloride→5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4,6-diol→4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine→4-(tert-butyl)benzenesulfonamide→4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide→ethane-1,2-diol
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 2-BROMO-5-HYDROXYBENZALDEHYDE Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-(4-Bromo-3-formyl-phenoxy)-benzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 4-[4-bromo-3-(hydroxymethyl)phenoxy]benzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | [2-bromo-5-(4-cyanophenoxy)phenyl]methyl acetate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.